Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: A phase III study

Journal of Clinical Oncology

Volumn 22, Issue 6, 2004, Pages 1118-1125

  Avril, Marie Françoise ^a   Aamdal, S ^b   Grob, J J ^b   Hauschild, A ^b   Mohr, P ^b   Bonerandi, J J ^b   Weichenthal, M ^b   Neuber, K ^b   Bieber, T ^b   Gilde, K ^b   Porta, V Guillem ^b   Fra, J ^b   Bonneterre, J ^b   Saiag P ^b   Kamanabrou, D ^b   Pehamberger, H ^b   Sufliarsky, J ^b   Larriba, J L Gonzalez ^b   Scherrer, A ^b   Menu, Y ^b  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DACARBAZINE; FOTEMUSTINE; ANTINEOPLASTIC AGENT; NITROSOUREA DERIVATIVE; ORGANOPHOSPHORUS COMPOUND;

ARTICLE; BRAIN METASTASIS; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SAFETY; HUMAN; MAJOR CLINICAL STUDY; MELANOMA; NEUTROPENIA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; THROMBOCYTOPENIA; ADULT; AGED; BRAIN TUMOR; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; EUROPE; FEMALE; MALE; METASTASIS; MIDDLE AGED; MULTICENTER STUDY; NONPARAMETRIC TEST; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; SKIN TUMOR; SURVIVAL;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; DACARBAZINE; DISEASE-FREE SURVIVAL; EUROPE; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; NITROSOUREA COMPOUNDS; ORGANOPHOSPHORUS COMPOUNDS; QUALITY OF LIFE; SKIN NEOPLASMS; STATISTICS, NONPARAMETRIC; SURVIVAL ANALYSIS;

EID: 1842562211     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.04.165     Document Type: Article

References (23)

1. Balch CM, Reinigen DS, Kirkwood JM: Cutaneous melanoma, in De Vita VT Jr, Hellman S, Rosenberg SA (eds): Cancer Principles and Practice of Oncology (ed 5). Philadelphia, PA, Lippincott-Raven, 1997, pp 1947-1994
2. Tilgen W: Malignant melanoma: Current therapeutic concepts. Onkologie 18:534-547, 1995
3. Serrone L, Zeuli M, Sega FM, et al: Dacarbazine-based chemotherapy for metastatic melanoma: Thirty year experience overview. J Exp Clin Cancer Res 19:21-34, 2000
4. Luce JK, Thurman WG, Isaacs BL, et al: Clinical trials with the antitumor agent 5-(3,3-dimethy-1-triazeno)imidazole-4-carboxamide. Cancer Chemother Rep 54:119-124, 1970
5. Hill GJ, Moss SE, Colomb FM, et al: DTIC and combination therapy for melanoma. Cancer 47:2556-2562, 1981
6. Falkson G, Van der Merwe AM, Falkson HC: Clinical experience with 5-(3,3-bis(2-chloro-ethyl)-1-triazeno)-imidazole-4-carboxamide (NSC 82196) in the treatment of metastatic malignant melanoma. Cancer Chemother Rep 56:671-677, 1972
7. Middleton MR, Lorigan P, Owen J. et al: A randomized phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and Interferon in advanced melanoma. Br J Cancer 82:1158-1162, 2000
8. Falkson CI, Ibrahim J, Kirkwood JM, et al: Phase III trial of dacarbazine versus dacarbazine with interferon α-2b and tamoxifen in patients with metastatic malignant melanoma: An Eastern Cooperative Oncology Group study. J Clin Oncol 16:1743-1751, 1998
9. Middleton MR, Grob JJ, Aaronson N, et al: Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 18:158-166, 2000
10. Jacquillat CI, Khayat D, Banzet P, et al: Final report of the French multicenter phase II study of the nitrosourea fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with cerebral metastases. Cancer 66:1873-1878, 1990
11. Jacquillat CI, Khayat D, Banzet P, et al: Chemotherapy by fotemustine in cerebral metastases of disseminated malignant melanoma. Cancer Chemother Pharmacol 25:263-266, 1990
12. Calabresi E, Aapro M, Becquart D, et al: Multicenter phase II trial of the single agent fotemustine in patients with advanced malignant melanoma. Ann Oncol 2:377-378, 1991
13. Kleeberg UR, Engel E, Israels P, et al: Phase II trial of fotemustine in patients with metastatic melanoma (EORTC-MCG 18881). Onkologie 14:81-83, 1991
14. Schallreuter KU, Wenzel E, Brassow FW, et al: Positive phase II study in the treatment of advanced malignant melanoma with fotemustine. Cancer Chemother Pharmacol 29:167-171, 1991
15. World Health Organization: Handbook for reporting results of cancer treatment. WHO publication no. 48. Geneva, Switzerland, World Health Organization, 1979
16. National Cancer Institute: Investigator's Handbook: A manual for participants in clinical trials of investigational agents sponsored by DCTD, NCI, Bethesda, MD, National Cancer Institute, 1993
17. Payers PM, Hopwood P, Harvey A, et al: Quality of life assessment in clinical trials guidelines and a checklist for protocol writers: The UK Medical Research Council Experience. Eur J Cancer 33:20-28, 1997
18. Aaronson NK, Ahmedzai S, Bergman B, et al: The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365-376, 1993
19. Chapman PB, Einhorn LH, Meyers ML, et al: Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 17:2745-2751, 1999
20. Mornex F, Thomas L, Mohr P, et al: A prospective randomised multicenter phase III trial of fotemustine plus whole brain irradiation versus fotemustine alone in cerebral metastases of malignant melanoma. Melanoma Res 13:97-103, 2003
21. Paul MJ, Summers Y, Calvert AH, et al: Effect of temozolomide on central nervous system relapse in patients with advanced melanoma. Melanoma Res 12:175-178, 2002
22. Margolin K, Atkins MB, Thompson JA, et al: Temozolomide and whole brain irradiation in melanoma metastatic to the brain: A phase II trial of the Cytokine Working Group. J Cancer Res Clin Oncol 128:214-218, 2002
23. Hwu WJ, Krown SE, Panageas KS, et al: Temozolomide plus thalidomide in patients with advanced melanoma: Results of a dose finding trial. J Clin Oncol 20:2610-2615, 2002